НАУЧНЫХ ИССЛЕДОВАНИЙ ПО ИЗУЧЕНИЮ НАСЛЕДСТВЕННАЯ ПРЕДРАСПОЛОЖЕННОСТЬ ВИРУСАМИ ГЕПАТИТА С (HCV) И В (HBV) НА МОЛЕКУЛЯРНОМ УРОВНЕ

1. Aileen Ferrer., Alan R Katz., Eric L Hurwitz., Thaddeus Pham. Hepatitis B Prevalence and Risk Factors in a Foreign-Born Asian and Pacific Islander Population at a Community Health Center in Hawaii. Asia Pacific Journal of Public Health. Volume 30, Issue 8, https://doi.org/10.1177/1010539518800359

2. Andri Rauch., Zoltan Kutalik., Patrick Descombes., Tao Cai., Julia Di Iulio et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010 Apr. 138(4):1338-45, 1345.e1-7. doi: 10.1053/j.gastro.

3. Anna S Lok., Fabien Zoulim., Geoffrey Dusheiko., Marc G Ghany. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017 Oct. 66(4):1296-1313. doi: 10.1002/hep.29323.

4. Ashoke Sharon, Chung K. Chu. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Research. Volume 80, Issue 3, December 2008, Pages 339-353. https://doi.org/10.1016/j.antiviral.2008.07.010

5. David L. Thomas, Chloe L. Thio, Maureen P. Martin, Ying Qi, Dongliang Ge, Colm O’hUigin, Judith Kidd, Kenneth Kidd, Salim I. Khakoo, Graeme Alexander, James J. Goedert, Gregory D. Kirk, Sharyne M. Donfield, Hugo R. Rosen, Leslie H. Tobler, Michael P. Busch, John G. McHutchison, David B. Goldstein & Mary Carrington. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009). https://doi.org/10.1038/nature08463

6. Dongliang Ge, Jacques Fellay, Alexander J. Thompson, Jason S. Simon, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen, Ping Qiu, Arthur H. Bertelsen, Andrew J. Muir, Mark Sulkowski, John G. McHutchison & David B. Goldstein. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009). https://doi.org/10.1038/nature08309

7. EASL Clinical practice guidelines: Management of chronic hepatitis B. Journal of Hepatology Volume 50, Issue 2, February 2009, Pages 227-242. https://doi.org/10.1016/j.jhep.2008.10.001

8. El-Serag, H.B. (2012) Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 142, 1264-1273. https://doi.org/10.1053/j.gastro.2011.12.061

9. Francis S Collins., Harold Varmus. A New Initiative on Precision Medicine. “The New England Journal of Medicine” 2015 February 30; 372(9):793–795. doi: 10.1056/NEJMp1500523.

10. Gang Chen., Wenyao Lin., Fumin Shen., Uchenna H Iloeje., W Thomas London., Alison A Evans. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. J Gastroenterol. 2006 Aug. 101(8):1797-803. doi: 10.1111/j.1572-0241.2006.00647.

11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]

12. Jeanette J McCarthy., Josephine H Li., Alexander Thompson., Sunil Suchindran., Xiang Qian Lao et al. Replicated Association between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. Gastroenterology. 2010 Feb 19;138(7):2307–2314. doi: 10.1053/j.gastro.2010.02.009

13. Luca Valenti., Alessio Aghemo., Albert Friedrich Stättermayer. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. Journal of Hepatology 2012 vol.56 1207-1217.

14. Marc G Ghany., Kristen M Marks., Timothy R Morgan., David L Wyles et al. Recommendations for Testing, Managing and Treating Hepatitis C virus infection. Hepatology. 2020 February. 71(2): 686-721, doi:10.1002/hep.31060.

15. Norah A Terrault., Anna S F Lok., Brian J McMahon., Kyong-Mi Chang., Jessica P Hwang., Maureen M Jonas., Robert S Brown Jr., Natalie H Bzowej., John B Wong. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr. 67(4):1560-1599. doi: 10.1002/hep.29800.

16. Peng Zhao., Jie Wen., Linyan Qian., Xiaojun Zhu., Hong Wang., Xiaoxia Bai.

Expression of S100 proteins is associated with HBV intrauterine transmission. Arch Gynecol Obstet. 2020 Dec. 302(6):1389-1399. doi: 10.1007/s00404-020-05753-6.

17. Petruzziello A., Marigliano S., Loquercio G., Cozzolino A., Cacciapuoti C. Global epidemiology of hepatits C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. Gastroenterology, 2016. September 14; 22(34):7824-7840.

http://www.wjgnet.com/esps/helpdesk.aspx/doi:10.3748/wjg.v22.i34.7824

18. Prokunina-Olsson, L., Muchmore, B., Tang, W. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45, 164–171 (2013).

https://doi.org/10.1038/ng.2521

19. Suppiah, V., Moldovan, M., Ahlenstiel, G. et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 41, 1100–1104 (2009). https://doi.org/10.1038/ng.447

20. Shan Ren., Junfeng Lu., Xiaofei Du., Yanxiang Huang., Lina Ma., Honglei Huo., Xinyue Chen., Lai Wei. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother. 2012 Feb 4;61(9):1433–1439. doi: 10.1007/s00262-012-1203-y

21. Shiying Li., Peng Hu., Qin-Qin Zhang., Ying-Hong Liu., Huai-Dong Hu., Da-Zhi Zhang., Hong Ren. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis of IL28B. Hepat Mon. 2011 Mar 1;11(3):163–172.

22. Stephen A Bustin., Jean-Francois Beaulieu., Jim Huggett., Rolf Jaggi., Frederick SB Kibenge., Pal A Olsvik., Louis C Penning., Stefan Toegel. MIQE précis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Molecular Biology 2010.

http://www.biomedcentral.com/1471-2199/11/74 .

23. Schrader C., Schielke A., Ellerbroek L., Johne R. PCR inhibitors-occurrence, properties and removal. J Appl Microbiol. 2012 Nov. 113(5):1014-26. doi: 10.1111/j.1365-2672.2012.05384.x.

24. Tanaka, Y., Nishida, N., Sugiyama, M. et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 41, 1105–1109 (2009). https://doi.org/10.1038/ng.449

25. Thio, C.L. (2009) Hepatitis B and Human Immunodeficiency Virus Coinfection. Hepatology, 49, S138-S145. https://doi.org/10.1002/hep.22883

https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.22883

26. Thomas, D., Thio, C., Martin, M. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009).

https://doi.org/10.1038/nature08463

27. World Health Organization (WHO). Hepatitis C. Key facts. Geneva: WHO; 2024.

https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

28. Xiaohui Zhang., Huaibin Zou., Yu Chen., Hua Zhang., Ruihua Tian., Jun Meng., Yunxia Zhu., Huimin Guo., Erhei Dai., Baoshen Zhu., Zhongsheng Liu., Yanxia Jin., Yujie Li., Liping Feng., Hui Zhuang., Calvin Q Pan., Jie Li., Zhongping Duan. The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: a prospective, multicenter, large-sample cohort study. BMC Med. 2021 Jul 13;19(1):148. doi: 10.1186/s12916-021-02025-1.

29. Yaohui Wang., Yinan Jiang., Jinxue Zhou., Wuhui Song., Jing Li., Mingli Wang., Jiuge Chen., Rui Xu., Jingjing Zhang., Fanni Ma., Youhai H Chen., Yuanfang Ma. Hepatitis C virus promotes hepatocellular carcinogenesis by targeting TIPE2, a new regulator of DNA damage response. Tumour Biol. 2016 Nov. 37(11):15265-15274. doi: 10.1007/s13277-016-5409-z.